Engineered immune cells take aim at multiple sclerosis and myasthenia gravis

NCT ID NCT07392528

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial will test a new treatment called QT-019C in up to 15 adults with relapsed or refractory neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. The treatment uses donor-derived CAR T-cells that target two proteins (CD19 and BCMA) on immune cells to potentially calm the overactive immune attack on the nervous system. The main goals are to check safety and find the right dose, with some early looks at whether it helps symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Universal allogeneic CAR T-cells targeting CD19 and BCMA
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat neurological autoimmune diseases like multiple sclerosis or myasthenia gravis.
What could go wrong
This is a very early, small trial with only 15 participants, so results may not apply broadly. There are also risks like severe immune reactions or nerve damage from the CAR T-cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Huanhu Hospital

    Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.